1. Home
  2. VRAX vs GTBP Comparison

VRAX vs GTBP Comparison

Compare VRAX & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Virax Biolabs Group Limited

VRAX

Virax Biolabs Group Limited

HOLD

Current Price

$0.42

Market Cap

2.9M

Sector

Health Care

ML Signal

HOLD

Logo GT Biopharma Inc.

GTBP

GT Biopharma Inc.

HOLD

Current Price

$0.79

Market Cap

2.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VRAX
GTBP
Founded
2013
1965
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.9M
2.6M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
VRAX
GTBP
Price
$0.42
$0.79
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$3.00
N/A
AVG Volume (30 Days)
908.5K
2.0M
Earning Date
01-01-0001
02-20-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,986.00
N/A
Revenue This Year
$217,274.83
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.31
$0.54
52 Week High
$3.20
$3.85

Technical Indicators

Market Signals
Indicator
VRAX
GTBP
Relative Strength Index (RSI) 50.89 53.76
Support Level $0.33 $0.75
Resistance Level $0.51 $0.87
Average True Range (ATR) 0.05 0.08
MACD 0.00 0.01
Stochastic Oscillator 56.11 52.92

Price Performance

Historical Comparison
VRAX
GTBP

About VRAX Virax Biolabs Group Limited

Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes (HSV-1) and Human Papillomavirus (HPV).

About GTBP GT Biopharma Inc.

GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.

Share on Social Networks: